Early experience with human papillomavirus vaccine introduction in the United States, Canada and Australia.
Successful incorporation of a new vaccine into a nation's vaccination program requires addressing a number of issues, including: 1) establishing national recommendations; 2) assuring education of and acceptance by the public and medical community; 3) establishing and maintaining an appropriate infrastructure for vaccine delivery; 4) financing the vaccine and the program, in addition to political will. This article reviews the early experience with implementation of human papillomavirus (HPV) vaccination programs. It focuses on the United States of America and Canada and provides a brief report on Australia, where introduction is underway.
Shefer
Abigail
A
National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA. ams7@CDC.GOV
Markowitz
Lauri
L
Deeks
Shelley
S
Tam
Theresa
T
Irwin
Kathleen
K
Garland
Suzanne M
SM
Schuchat
Anne
A
D001315:Australia; D002170:Canada; D006298:Health Services Administration; D006801:Humans; D030361:Papillomavirus Infections / Q000517:prevention & control*; D053918:Papillomavirus Vaccines / Q000191:economics* / Q000592:standards* / Q000600:supply & distribution; D014481:United States; D014611:Vaccination
D053918:Papillomavirus Vaccines